Open-label pilot study of combination therapy with rosiglitazone and bexarotene in the treatment of cutaneous T-cell lymphoma.
Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.
Sepmeyer
Jacob A
JA
Vanderbilt University School of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232-5227, USA
Greer
John P
JP
Koyama
Tatsuki
T
Zic
John A
JA
D000368:Aged; D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D000077610:Bexarotene; D001707:Biopsy, Needle; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D008297:Male; D020714:Maximum Tolerated Dose; D008875:Middle Aged; D009367:Neoplasm Staging; D010865:Pilot Projects; D018570:Risk Assessment; D000077154:Rosiglitazone; D016037:Single-Blind Method; D016019:Survival Analysis; D013764:Tetrahydronaphthalenes / Q000008:administration & dosage*; D045162:Thiazolidinediones / Q000008:administration & dosage*; D016896:Treatment Outcome
D016588:Anticarcinogenic Agents; D013764:Tetrahydronaphthalenes; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D000077610:Bexarotene